前列腺癌辐射治疗方式的差异
Mitchell Alameddine1, Shan Wu1, Oluwaseun Orikogbo1
1Division of Health Services Research, Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Urologic oncology
|August 30, 2025
概括
在接受晚期前列腺癌辐射治疗方面,种族和民族少数群体和农村地区的人群存在差异. 了解这些差异是关键的,因为刻板体辐射疗法 (SBRT) 的使用越来越多.
科学领域:
- 癌症学
- 辐射瘤学
- 医疗服务研究
背景情况:
- 立体辐射疗法 (SBRT) 和强度调节辐射疗法 (IMRT) 是前列腺癌的主要辐射疗法.
- 在过去的十年中,SBRT的采用量显著增加.
- 在前列腺癌患者中影响SBRT选择的因素尚不清楚.
研究的目的:
- 描述前列腺癌的放射治疗选择.
- 确定与SBRT和IMRT吸收相关的因素.
- 阐明前列腺癌放射治疗中不同治疗决策的驱动因素.
主要方法:
- 从SEER-Medicare数据集 (2008-2017) 中分析了1,624名前列腺癌患者.
- 专注于用SBRT或IMRT治疗局部前列腺癌的白人和黑人患者.
- 患者人口统计和诊断到治疗的时间比较.
主要成果:
- 与白人种族相比,黑人种族接受SBRT的几率较低 (OR: 0. 4).
- 西班牙裔与非西班牙裔相比,SBRT的几率降低 (OR: 0. 4).
- 在人口较少的地区 (< 25万) 的患者更有可能接受SBRT (OR: 3. 6).
结论:
- 对于前列腺癌的SBRT与IMRT选择存在显著差异.
- 了解这些治疗模式的差异对于未来的干预至关重要.
- 这些发现突显了需要解决不平等问题,因为SBRT变得越来越普遍.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
7.3K
相关概念视频
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K